Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
Advertisement
CBD
Canada
Cannabidiol
Cannabis
Retail
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
15
06
2020
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
6
8
2021
Statut:
epublish
Résumé
In Canada, the legalization of cannabis has enabled cannabidiol (CBD) to become a popular commercial product, increasingly used for medical or therapeutic purposes. There are currently over one thousand CBD products available globally, ranging from oil extracts to CBD-infused beverages. Despite increased usage and availability, the evidence supporting the medical efficacy of CBD is limited. Anecdotal evidence suggests CBD sellers represent their products for medical use through direct medical claims or advice, which in Canada, is not allowed under the Cannabis Act without Health Canada approval. However, it is not clear the extent of sellers making health claims or other strategies used to promote medical usage of CBD. The objective of this study is to determine how CBD sellers advertise their products online to consumers. The product descriptions of 2165 CBD products from 70 websites selling CBD products for human consumption in Canada were collected from January 14th CBD products are framed to prospective customer through three distinct frames: a specific cure or treatment (n = 1153), a natural health product (n = 872), and a product used in certain ways to achieve particular results (n = 1388). Product descriptions contained medical or therapeutic claims for 171 medical conditions and ailments, with 53.3% of products containing at least one claim. The most prevalent claims found in product descriptions were the ability to treat or manage pain (n = 824), anxiety (n = 609), and inflammation (n = 545). Claims were found for treating or managing serious and-life-threatening illnesses such as multiple sclerosis (n = 210), arthritis (n = 179), cancer (n = 169), Crohn's disease (n = 78), Parkinson's disease (n = 59), and human immunodeficiency virus (HIV) (n = 54). CBD most often came in oil/tincture/concentrate form (n = 755), followed by edibles (n = 428), and vaporizer pen/cartridge/liquid products (n = 290). The findings suggest CBD is represented as a medical option for numerous conditions and ailments. We recommend Health Canada to conduct a systematic audit of companies selling CBD for regulatory adherence.
Sections du résumé
BACKGROUND
In Canada, the legalization of cannabis has enabled cannabidiol (CBD) to become a popular commercial product, increasingly used for medical or therapeutic purposes. There are currently over one thousand CBD products available globally, ranging from oil extracts to CBD-infused beverages. Despite increased usage and availability, the evidence supporting the medical efficacy of CBD is limited. Anecdotal evidence suggests CBD sellers represent their products for medical use through direct medical claims or advice, which in Canada, is not allowed under the Cannabis Act without Health Canada approval. However, it is not clear the extent of sellers making health claims or other strategies used to promote medical usage of CBD. The objective of this study is to determine how CBD sellers advertise their products online to consumers.
METHODS
The product descriptions of 2165 CBD products from 70 websites selling CBD products for human consumption in Canada were collected from January 14th
RESULTS
CBD products are framed to prospective customer through three distinct frames: a specific cure or treatment (n = 1153), a natural health product (n = 872), and a product used in certain ways to achieve particular results (n = 1388). Product descriptions contained medical or therapeutic claims for 171 medical conditions and ailments, with 53.3% of products containing at least one claim. The most prevalent claims found in product descriptions were the ability to treat or manage pain (n = 824), anxiety (n = 609), and inflammation (n = 545). Claims were found for treating or managing serious and-life-threatening illnesses such as multiple sclerosis (n = 210), arthritis (n = 179), cancer (n = 169), Crohn's disease (n = 78), Parkinson's disease (n = 59), and human immunodeficiency virus (HIV) (n = 54). CBD most often came in oil/tincture/concentrate form (n = 755), followed by edibles (n = 428), and vaporizer pen/cartridge/liquid products (n = 290).
CONCLUSION
The findings suggest CBD is represented as a medical option for numerous conditions and ailments. We recommend Health Canada to conduct a systematic audit of companies selling CBD for regulatory adherence.
Identifiants
pubmed: 34210299
doi: 10.1186/s12889-021-11282-x
pii: 10.1186/s12889-021-11282-x
pmc: PMC8248754
doi:
Substances chimiques
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1285Références
Am J Public Health. 2020 Oct;110(S3):S294-S299
pubmed: 33001729
JAMA Netw Open. 2020 Oct 1;3(10):e2020977
pubmed: 33057645
J Cannabis Res. 2020 Jan 2;2(1):2
pubmed: 33526132
Cannabis Cannabinoid Res. 2020 Nov 20;:
pubmed: 33998872
Soc Sci Med. 2012 Apr;74(8):1274-81
pubmed: 22386639
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):274-278
pubmed: 33381640
J Diet Suppl. 2020;17(5):493-502
pubmed: 32543246
Neurol Sci. 2020 Nov;41(11):3085-3098
pubmed: 32556748
J Cannabis Res. 2021 May 6;3(1):13
pubmed: 33957993
Psychiatr Serv. 2021 Apr 1;72(4):429-436
pubmed: 33530732